6th German Pharm-Tox Summit

87th Annual Meeting of the
German Society for Experimental and Clinical Pharmacology and Toxicology (DGPT)
With contribution of AGAH
1 – 3 March 2021 • Digital

6th German Pharm-Tox Summit

87th Annual Meeting of the
German Society for Experimental and Clinical Pharmacology and Toxicology (DGPT)
With contribution of AGAH
1 – 3 March 2021 • Digital

Conference Details

Abstract Submission

Session Planner

Print-File

Advanced Courses - The log-in data to the courses will be send out on Monday, March 1rst, 2021 at 7am.

Date: March 1st, 2021

Applications of genome editing techniques in model systems of Experimental Pharmacology

13:00Welcome
Marc Freichel, Heidelberg and Susanne Lutz, Göttingen
13:15How to CRISPR: precise and efficient genome editing
Thomas Thumberger, Heidelberg
14:00Engineering CRISPR cell lines and mouse models – advances & challenges
Rebekka Medert, Heidelberg
14:45Break
15:15Programming Biology: engineering transcription via CRISPR/Cas9 to control cell behaviour
Laura Zelarayan, Göttingen
16:00Testing of CRISPR treatments in cardiovascular diseases
Lucas Cyganek, Göttingen
16:45Final discussion

Date: March 1st, 2021

14:00Recognition and prediction of pharmacological effects - non-invasive in-vivo imaging (focus on MRI)
Andreas Hess, Erlangen
15:00New possibilities for microscopic imaging with confocal microscopes, superresolution STED and Minflux
Karsten Bahlmann, Cambridge, MA, USA
16:00PET imaging in determination of drug disposition
Oliver Langer, Wien

Computational/in silicoToxicology/QSARs – Implementation and Assessment in the Regulatory Context
Date: March 1st, 2021

10:00Welcome and Introductory Remarks
Michael Werner, Prosacon
10:20The use and assessment of QSAR predictions under REACH
Andrea Gissi, ECHA
10:55Use of QSAR/Read Across for the evaluation of pesticide metabolites and impurities – An industry perspective
Markus Frericks, BASF
11:30Coffee Break
11:45Application of SAR and modelling in pharmaceutical and medical device industry: Secondary pharmacology modelling (e.g. CiPA initiative), Nitrosamines in the context of ICH M7 and implications for risk assessment for Medical Devices
Andreas Czich, Sanofi
Susanne Dorn, knoell
12:20Lunch Break + General Meeting
Working Group Regulatory Toxicology
13:45Endocrine Disruptors – regulatory use of in silico as part of alternative methods
Vera Ritz, BfR
14:20How to perform risk assessment of a new cosmetic ingredient using new approach methodologies? - Systemic exposure assessment and SAR based read across applied to oxidative hair dyes
Carsten Goebel, Wella Company
14:55In Silico Toxicology Protocols – defining standards and best practices towards mutual acceptance of data
Glenn Myatt, Leadscope
15:30Coffee Break
15:45Panel discussion – Challenges in the further application of in silico models and tools
Jochen vom Brocke, ECHA
Monika Batke, University Emden/Leer
All Panellists